DGCI gives emergency approval of DRDO-developed anti-Covid oral drug | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 10, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 10, 2025
DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

Coronavirus chronicle

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

DGCI gives emergency approval of DRDO-developed anti-Covid oral drug

The oral drug has been developed by Institute of Nuclear Medicine and Allied Sciences, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. Phase III clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence

Hindustan Times
08 May, 2021, 02:25 pm
Last modified: 08 May, 2021, 02:28 pm
Indian Prime Minister Narendra Modi. Photo: NDTV
Indian Prime Minister Narendra Modi. Photo: NDTV

An anti-Covid-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy's Laboratories, Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients. The drug will be of immense benefit to the people suffering from Covid in the ongoing pandemic.

Pursuing the Hon'ble Prime Minister's call for preparedness against the pandemic, DRDO took the initiative of developing anti-Covid therapeutic application of 2-DG. In April 2020, during the first wave of pandemic INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad and found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. Based on these results, Drugs Controller General of India's (DCGI) Central Drugs Standard Control Organization (CDSCO) permitted Phase-II clinical trial of 2-DG in Covid-19 patients in May 2020.

DRDO along with its industry partner Dr Reddy's Laboratories (DRL, Hyderabad) started the clinical trials to test the safety and efficacy of the drug in Covid-19 patients. In Phase-II trials (including dose ranging) conducted during May to October 2020, the drug was found to be safe in Covid-19 patients, and showed significant improvement in their recovery. Phase IIa was conducted in 6 hospitals and Phase IIb (dose ranging) clinical trial was conducted at 11 hospitals all over the country. Phase-II trial was conducted on 110 patients. In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints. A significantly favourable trend (2.5 days difference) was seen in terms of the median time to achieving normalization of specific vital signs parameters when compared to SOC.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Top News / World+Biz

DGCI / Defence Research and Development Organisation (DRDO) / Covid oral drug / oral drug

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Council of Advisers' meeting on Thursday (10 July). Photo: CA Press Wing
    Govt okays establishing UN human rights office in Dhaka for 3 years
  • No final consensus yet on CJ appointment from senior-most judges: Salahuddin
    No final consensus yet on CJ appointment from senior-most judges: Salahuddin
  • National Consensus Commission chief Ali Riaz speaks at the Foreign Service Academy in the capital’s Bailey Road on 10 July 2025. Photo: Collected
    Chief justice appointment: Consensus reached on two key issues, says Ali Riaz

MOST VIEWED

  • Graphics: TBS
    BB raises startup fund limit, drops upper age barrier
  • Workers pack undergarments at the packing section of a garment factory in Ashulia, on the outskirts of Dhaka, Bangladesh, April 19, 2025. Photo: REUTERS/Fatima Tuj Johora
    After US tariffs, jobs hang by a thread in Bangladesh's garments sector
  • Global Islami Bank rectifies 2023 figures, reports Tk2,259cr loss instead of Tk128cr profit
    Global Islami Bank rectifies 2023 figures, reports Tk2,259cr loss instead of Tk128cr profit
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Audit reports of most banks contain cooked up data: BB governor
  • File photo of containers at Chattogram port/TBS
    US buyers push Bangladeshi exporters to share extra tariff costs
  • CA orders law enforcers to complete all election preparations by December
    CA orders law enforcers to complete all election preparations by December

Related News

  • India showcases naval ballistic missile defence capability in maiden test
  • Beximco to produce Pfizer’s Covid-19 drug locally 
  • Beximco Pharma gets license for oral anti-Covid drug
  • Incepta launches Pfizer’s anti-Covid pill
  • WHO-led program aims to buy antiviral Covid-19 pills for $10

Features

Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

45m | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

3h | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered- have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

3h | Panorama
Women are forced to fish in saline waters every day, risking their health to provide for their families. Photo: TBS

How Mongla’s women are bearing the brunt of rising salinity

1d | Panorama

More Videos from TBS

Will the title 'Honorable and Excellency' be abolished?

Will the title 'Honorable and Excellency' be abolished?

20m | TBS Today
We want to recognize the July Uprising on a national level: Salahuddin Ahmed

We want to recognize the July Uprising on a national level: Salahuddin Ahmed

5m | TBS Today
July-August mass uprising: Rakib explains Chatradal's role in Jatrabari

July-August mass uprising: Rakib explains Chatradal's role in Jatrabari

1h | TBS Stories
News of The Day, 10 JULY 2025

News of The Day, 10 JULY 2025

1h | TBS News of the day
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net